{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:22:39Z","timestamp":1790652159378,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T00:00:00Z","timestamp":1589328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T00:00:00Z","timestamp":1589328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["108257"],"award-info":[{"award-number":["108257"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Five-year survival has increased for many hematologic malignancies in the 21st century. However, whether this has translated into greater long-term survival is unknown. Here, we examine 10- and 20-year survival for patients with multiple myeloma (MM), acute lymphoblastic leukemia (ALL), acute myeloblastic leukemia (AML), chronic lymphoid leukemia (CLL), chronic myeloid leukemia (CML), non-Hodgkin lymphoma (NHL), and Hodgkin lymphoma (HL). Data were extracted from the Surveillance, Epidemiology, and End Results-9 database. Patients age 15+ with the above malignancies were included. The newly developed boomerang method was used to examine 10- and 20-year relative survival (RS) for patients in 2002\u20132006 and 2012\u201316. Ten and 20-year RS increased for each malignancy examined, with increases ranging from +4.4% units for 20-year RS for AML to +23.1% units for 10-year RS for CML. Ten year RS was &gt;50% in 2012\u201316 for patients with CLL, CML, HL, NHL, and DLBCL, at 77.1%, 62.1%, 63.9%, 64.5%, and 63.0%, respectively. Survival dropped between 10 and 20 years after diagnosis for most malignancies. Long-term survival is increasing for common hematologic malignancies, but late mortality is an ongoing issue. Further study of long-term outcomes in curable malignancies to determine the reason for these later decreases in survival is indicated.<\/jats:p>","DOI":"10.1038\/s41408-020-0323-4","type":"journal-article","created":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T15:06:34Z","timestamp":1589382394000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":119,"title":["Changes in long term survival after diagnosis with common hematologic malignancies in the early 21st century"],"prefix":"10.1038","volume":"10","author":[{"given":"Dianne","family":"Pulte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,13]]},"reference":[{"key":"323_CR1","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1002\/cncr.30003","volume":"122","author":"D Pulte","year":"2016","unstructured":"Pulte, D., Jansen, L., Castro, F. A. & Brenner, H. Changes in the survival of older patients with hematologic malignancies in the early 21st century. Cancer 122, 2031\u201340. (2016).","journal-title":"Cancer"},{"key":"323_CR2","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/ejh.12743","volume":"97","author":"N Gunnarsson","year":"2016","unstructured":"Gunnarsson, N. et al. Population-based assessment of chronic myeloid leukemia in Sweden: striking increase in survival and prevalence. Eur. J. Haematol. 97, 387\u201392. (2016).","journal-title":"Eur. J. Haematol"},{"key":"323_CR3","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1756-8722-6-70","volume":"6","author":"D Pulte","year":"2013","unstructured":"Pulte, D. et al. Population level survival of patients with chronic myelocytic leukemia in Germany compared to the US in the early 21st century. J. Hematol Oncol. 6, 70 (2013).","journal-title":"J. Hematol Oncol."},{"key":"323_CR4","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/ejh.12468","volume":"94","author":"D Pulte","year":"2015","unstructured":"Pulte, D., Redaniel, M. T., Bird, J. & Jeffreys, M. Survival for patients with chronic leukemias in the US and Britain: age-related disparities and changes in the early 21st century. Eur. J. Haematol. 94, 540\u2013545 (2015).","journal-title":"Eur. J. Haematol"},{"key":"323_CR5","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/bjh.12465","volume":"163","author":"S Pozzi","year":"2013","unstructured":"Pozzi, S. et al. Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis. Br. J. Haematol. 163, 40\u201346 (2013).","journal-title":"Br. J. Haematol"},{"key":"323_CR6","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/bjh.13537","volume":"171","author":"D Pulte","year":"2015","unstructured":"Pulte, D. et al. Trends in survival of multiple myeloma patients in Germany and the United States in the first decade of the 21st century. Br. J. Haematol. 171, 189\u201396. (2015).","journal-title":"Br. J. Haematol."},{"key":"323_CR7","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1001\/archinternmed.2007.125","volume":"168","author":"D Pulte","year":"2008","unstructured":"Pulte, D., Gondos, A. & Brenner, H. Ongoing improvement in outcomes for patients diagnosed as having non-Hodgkin lymphoma from the 1990s to the early 21st century. Arch. Intern. Med. 168, 469\u2013476 (2008).","journal-title":"Arch. Intern. Med."},{"key":"323_CR8","first-page":"1972","volume":"9","author":"JR Johnson","year":"2003","unstructured":"Johnson, J. R. et al. Approval summary: Imatinib mesylate capsules for treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeologenous leukemia in chronic phase. Clin. Cancer Res. 9, 1972\u20131979 (2003).","journal-title":"Clin. Cancer Res."},{"key":"323_CR9","doi-asserted-by":"publisher","first-page":"4405","DOI":"10.1200\/JCO.2002.99.060","volume":"20","author":"H Brenner","year":"2002","unstructured":"Brenner, H. & Hakulinen, T. Very-long-term survival rates of patients with cancer. J. Clin. Oncol. 20, 4405\u20134409 (2002).","journal-title":"J. Clin. Oncol"},{"key":"323_CR10","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.jclinepi.2015.09.017","volume":"70","author":"H Brenner","year":"2016","unstructured":"Brenner, H. & Jansen, L. Timely disclosure of progress in long-term cancer survival: the boomerang method substantially improved estimates in a comparative study. J. Clin. Epidemiol. 70, 224\u2013232 (2016).","journal-title":"J. Clin. Epidemiol."},{"key":"323_CR11","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) Research Data (1973\u20132012), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2016, based on the November 2015 submission."},{"key":"323_CR12","first-page":"1","volume":"64","author":"E Arias","year":"2015","unstructured":"Arias, E. United States life tables, 2011. Natl Vital. Stat. Rep. 64, 1\u201363 (2015).","journal-title":"Natl Vital. Stat. Rep."},{"key":"323_CR13","unstructured":"Ederer F., H. H. Instructions to IBM 650 programmers in processing survival computations. (National Cancer Institute, Bethesda, MD, 1959)."},{"key":"323_CR14","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1016\/j.ejca.2004.07.002","volume":"40","author":"I Corazziari","year":"2004","unstructured":"Corazziari, I., Quinn, M. & Capocaccia, R. Standard cancer patient population for age standardizing survival ratios. Eur. J. Cancer 40, 2307\u20132316 (2004).","journal-title":"Eur. J. Cancer"},{"key":"323_CR15","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1182\/blood-2007-10-115493","volume":"111","author":"H Brenner","year":"2008","unstructured":"Brenner, H., Gondos, A. & Pulte, D. Ongoing improvement in long-term survival of patients with Hodgkin disease at all ages and recent catch-up of older patients. Blood 111, 2977\u20132983 (2008).","journal-title":"Blood"},{"key":"323_CR16","doi-asserted-by":"publisher","first-page":"3076","DOI":"10.1182\/blood-2014-09-568915","volume":"125","author":"P Moreau","year":"2015","unstructured":"Moreau, P., Attal, M. & Facon, T. Frontline therapy of multiple myeloma. Blood 125, 3076\u20133084 (2015).","journal-title":"Blood"},{"key":"323_CR17","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1001\/jama.2014.14553","volume":"312","author":"C Nabhan","year":"2014","unstructured":"Nabhan, C. & Rosen, S. T. Chronic lymphocytic leukemia: a clinical review. JAMA 312, 2265\u20132276 (2014).","journal-title":"JAMA"},{"issue":"Suppl2","key":"323_CR18","doi-asserted-by":"publisher","first-page":"S141","DOI":"10.1007\/s00277-015-2322-2","volume":"94","author":"M Baccarani","year":"2015","unstructured":"Baccarani, M., Castagnetti, F., Gugliotta, G. & Rosti, G. A review of the European LeukemiaNet recommendations for the management of CML. Ann. Hematol. 94(Suppl2), S141\u2013S147 (2015).","journal-title":"Ann. Hematol."},{"key":"323_CR19","first-page":"280","volume":"18","author":"A Sawas","year":"2011","unstructured":"Sawas, A., Diefenbach, C. & O\u2019Connor, O. A. New therapeutic targets and drugs in non-Hodgkin\u2019s lymphoma. Curr. Opin. Hematol. 18, 280\u2013287 (2011).","journal-title":"Curr. Opin. Hematol."},{"key":"323_CR20","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1002\/cncr.29383","volume":"121","author":"E Jabbour","year":"2015","unstructured":"Jabbour, E., O\u2019Brien, S., Konopleva, M. & Kantarjian, H. New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia. Cancer 121, 2517\u201328. (2015).","journal-title":"Cancer"},{"key":"323_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/ejh.12347","volume":"93","author":"DA Eichenauer","year":"2014","unstructured":"Eichenauer, D. A. & Engert, A. Antibodies and antibody-drug conjugates in the treatment of Hodgkin lymphoma. Eur. J. Haematol. 93, 1\u20138 (2014).","journal-title":"Eur. J. Haematol."},{"key":"323_CR22","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s11899-014-0205-6","volume":"9","author":"EH Cull","year":"2014","unstructured":"Cull, E. H. & Altman, J. K. Contemporary treatment of APL. Curr. Hematol. Malig. Rep. 9, 193\u2013201 (2014).","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"323_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0085554","volume":"9","author":"D Pulte","year":"2014","unstructured":"Pulte, D. et al. Survival of adults with acute lymphoblastic leukemia in Germany and the United States. PLoS ONE. 9, e85554 (2014).","journal-title":"PLoS ONE."},{"key":"323_CR24","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1002\/ijc.30186","volume":"139","author":"D Pulte","year":"2016","unstructured":"Pulte, D. et al. Survival in patients with acute myeloblastic leukemia in Germany and the United States: major differences in survival in young adults. Int. J. Cancer 139, 1289\u20131296 (2016).","journal-title":"Int. J. Cancer"},{"key":"323_CR25","doi-asserted-by":"publisher","first-page":"222","DOI":"10.3324\/haematol.2012.063602","volume":"98","author":"D Pulte","year":"2013","unstructured":"Pulte, D., Redaniel, M. T., Jansen, L., Brenner, H. & Jeffreys, M. Recent trends in survival of adult patients with acute leukemia: overall improvements, but persistent and partly increasing disparity in survival of patients from minority groups. Haematologica. 98, 222\u2013229 (2013).","journal-title":"Haematologica."},{"key":"323_CR26","doi-asserted-by":"publisher","first-page":"4973","DOI":"10.1002\/cncr.24548","volume":"115","author":"D Pulte","year":"2009","unstructured":"Pulte, D., Gondos, A. & Brenner, H. Trends in survival after diagnosis with hematologic malignancy in adolescence or young adulthood in the United States, 1981\u20132005. Cancer 115, 4973\u20134979 (2009).","journal-title":"Cancer"},{"key":"323_CR27","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","volume":"34","author":"H Bower","year":"2016","unstructured":"Bower, H. et al. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J. Clin. Oncol. 34, 2851\u20132857 (2016).","journal-title":"J. Clin. Oncol."},{"key":"323_CR28","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1200\/JCO.2015.65.4582","volume":"34","author":"DM Stephens","year":"2016","unstructured":"Stephens, D. M. et al. Continued risk of relapse independent of treatment modality in limited-stage diffuse large B-cell lymphoma: final and long-term analysis of Southwest Oncology Group Study S8736. J. Clin. Oncol. 34, 2997\u20133004 (2016).","journal-title":"J. Clin. Oncol."},{"key":"323_CR29","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1182\/blood-2012-02-409821","volume":"120","author":"JM Yeh","year":"2012","unstructured":"Yeh, J. M. & Diller, L. Pediatric Hodgkin lymphoma: trade-offs between short- and long-term mortality risks. Blood 120, 2195\u20132202 (2012).","journal-title":"Blood"},{"key":"323_CR30","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.3109\/10428194.2014.974043","volume":"56","author":"N Areethamsirikul","year":"2015","unstructured":"Areethamsirikul, N. & Reece, D. E. The risk of secondary primary malignancies after therapy for multiple myeloma. Leuk. Lymphoma. 56, 3012\u20133021 (2015).","journal-title":"Leuk. Lymphoma."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0323-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0323-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0323-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T14:28:26Z","timestamp":1670250506000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0323-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,13]]},"references-count":30,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,5]]}},"alternative-id":["323"],"URL":"https:\/\/doi.org\/10.1038\/s41408-020-0323-4","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,13]]},"assertion":[{"value":"2 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"56"}}